Beneficial Effects of Omega-3 Fatty Acids on Low Density Lipoprotein Particle Size in Patients with Type 2 Diabetes Already under Statin Therapy.
10.4093/dmj.2013.37.3.207
- Author:
Myung Won LEE
1
;
Jeong Kyung PARK
;
Jae Won HONG
;
Kwang Joon KIM
;
Dong Yeob SHIN
;
Chul Woo AHN
;
Young Duk SONG
;
Hong Keun CHO
;
Seok Won PARK
;
Eun Jig LEE
Author Information
1. Department of Endocrinology, Gwangmyeong Sung Ae Hospital, Gwangmyeong, Korea.
- Publication Type:Brief Communication ; Randomized Controlled Trial
- Keywords:
Diabetes mellitus, type 2;
Dyslipidemia;
Fatty acids, omega-3;
Hypertriglyceridemia;
Low density lipoprotein particle
- MeSH:
Cholesterol;
Cholesterol, LDL;
Diabetes Mellitus, Type 2;
Dyslipidemias;
Fatty Acids, Omega-3;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hypertriglyceridemia;
Korea;
Lipoproteins;
Particle Size
- From:Diabetes & Metabolism Journal
2013;37(3):207-211
- CountryRepublic of Korea
- Language:English
-
Abstract:
Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (> or =200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8%+/-3.1% vs. 2.3%+/-3.6%, P=0.024; -41.0%+/-24.1% vs. -24.2%+/-31.9%, P=0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.
